Grace Therapeutics, Inc.
Grace Therapeutics, Inc. is listed today as Grace Therapeutics, Inc.: market value, financials and filings are on its company page.
Funding rounds
0 counted as startup funding, 3 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Aug 2026 | $10 M | Private placement after listing | $10 to $50 million | equity | SEC | |
| Feb 2025 | $15 M | Private placement after listing | $10 to $50 million | equity, options | SEC | |
| Sep 2023 | $8 M | Private placement after listing | $2 to $10 million | equity, options | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Grace Therapeutics, Inc. had no revenue when it filed its newest notice of a funding round (Aug 2026).
SEC Form D (revenue range) · Aug 2026
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Aug 2026
Products and services#
No products or services of Grace Therapeutics, Inc. are on record.
Investors#
No investor of Grace Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete.
Largest shareholders today
Institutions holding Grace Therapeutics, Inc. shares, as of Sep 30, 2026.
- Opaleye Management Inc.$6 M13.30%
- Cerity Partners LLC$2 M4.04%
- Eversept Partners, LP$2 M3.66%
- Bank Of America Corp /de/$1 M2.35%
- Nantahala Capital Management, LLC$1 M2.26%
- Rosalind Advisors, Inc.$1 M2.26%
- ADAR1 Capital Management, LLC$1 M2.26%
- Vanguard Capital Management LLC$1 M1.90%
- Renaissance Technologies LLC$0 M0.88%
- Two Sigma Investments, LP$0 M0.60%
- Cantor Fitzgerald, L. P.$0 M0.48%
- Citadel Advisors LLC$0 M0.32%
- Jane Street Group, LLC$0 M0.30%
- Susquehanna International Group, LLP$0 M0.26%
- BlackRock, Inc.$0 M0.17%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Amresh Loch Kumar | VP of Program Management | Aug 2026 |
| Dr. R. Loch Macdonald | Chief Medical Officer | Aug 2026 |
| Prashant Kohli | Chief Executive Officer | Aug 2026 |
| Robert J. DelAversano | Vice President, Finance, Principal Financial Officer and Principal Accounting Officer | Aug 2026 |
| Amresh Kumar | VP of Program Management | Feb 2025 |
| Carrie D'Andrea | VP Clinical Operations | Feb 2025 |
| Brian Ford | Interim Chief Financial Officer | Oct 2023 |
| A. Brian Davis | Director | Aug 2026 |
| Edward George Neugeboren | Director | Aug 2026 |
| Prashant Kohli | Chief Executive Officer | Aug 2026 |
| S. George Kottayil | Director | Aug 2026 |
| Vimal Kavuru | Director | Aug 2026 |
| Edward Neugeboren | Director | Feb 2025 |
| Donald Olds | Director | Oct 2023 |
| Michael Derby | Director | Oct 2023 |
Went public since 2017. Its SEC number is that of a company listed on a stock exchange.